Table 3.
Rates of minor errors (mE), major errors (ME) and very major errors (VME)
|
Alere |
Biomérieux |
||||||
|---|---|---|---|---|---|---|---|
|
mE, n (%) |
ME, n (%) |
VME, n (%) |
mE, n (%) |
ME, n (%) |
VME, n (%) |
||
|
Ceftriaxone |
CLSI |
– |
0/46 (0) |
0/4 (0) |
– |
0/46 (0) |
0/4 (0) |
|
BD |
– |
0/46 (0) |
0/4 (0) |
– |
0/46 (0) |
0/4 (0) |
|
|
Oxoid |
– |
0/46 (0) |
0/4 (0) |
– |
0/46 (0) |
0/4 (0) |
|
|
Cefixime |
CLSI |
– |
2/41 (4.9) |
4/9 (44.4) |
– |
0/41 (0) |
5/9 (55.6) |
|
BD |
– |
1/41 (2.4) |
0/9 (0) |
– |
0/41 (0) |
2/9 (22.2) |
|
|
Oxoid |
– |
0/41 (0) |
4/9 (44.4) |
– |
0/41 (0) |
3/9 (33.3) |
|
|
Azithromycin |
CLSI |
– |
0/35 (0) |
6/15 (40) |
– |
1/35 (2.9) |
3/15 (20) |
|
BD |
– |
0/35 (0) |
5/15 (33.3) |
– |
0/35 (0) |
3/15 (20) |
|
|
Oxoid |
– |
0/35 (0) |
2/15 (16.7) |
– |
0/35 (0) |
1/15 (6.7) |
|
|
Tetracycline |
CLSI |
29/50 (58) |
0/7 (0) |
1/23 (4.3) |
31/50 (62) |
0/7 (0) |
0/23 (0) |
|
BD |
11/50 (22) |
0/7 (0) |
1/23 (4.3) |
18/50 (36) |
0/7 (0) |
1/23 (4.3) |
|
|
Oxoid |
24/50 (48) |
0/7 (0) |
0/23 (0) |
30/50 |
0/7 (0) |
1/23 (4.3) |
|